National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedZeidan AM, Gore SD, McNally DL
AHRQ Author: Davidoff AJ
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
The authors examined the use of lenalidomide in the Medicare population. They found that reductions in transfusion rates were overall consistent with data from clinical trials, and response rates were higher when ≥ 3 lenalidomide cycles were received.
AHRQ-authored.
Citation: Zeidan AM, Gore SD, McNally DL .
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Cancer 2013 Nov 1;119(21):3870-8. doi: 10.1002/cncr.28298.
.
.
Keywords: Comparative Effectiveness, Elderly, Medicare, Medication
Navarro-Millán I, Sattui SE, Curtis JR
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.
The objective of this article is to conduct a systematic review of the available literature on discontinuation of anti-tumor necrosis factor (anti-TNF) agents in rheumatoid arthritis (RA) patients and the associated features of study designs, including eligibility criteria, outcome definitions, and outcomes of discontinuation. The authors concluded that discontinuation of anti-TNF therapy is achievable for many RA patients who start in clinical remission or low disease activity.
AHRQ-funded; HS018517
Citation: Navarro-Millán I, Sattui SE, Curtis JR .
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.
Clin Ther. 2013 Nov;35(11):1850-61.e1. doi: 10.1016/j.clinthera.2013.09.015..
Keywords: Comparative Effectiveness, Outcomes, Arthritis, Medication, Chronic Conditions
Raebel MA, Xu S, Goodrich GK
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
This study sought to identify predictors of initiating any antihyperglycemic medication, and specifically sulfonylurea versus metformin in patients with newly diagnosed with diabetes. Most (59.7 percent) patients with newly diagnosed diabetes did not start any antihyperglycemic medication. Among those who did, metformin was generally the first antihyperglycemic initiated.
AHRQ-funded; HS019859
Citation: Raebel MA, Xu S, Goodrich GK .
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
Ann Pharmacother. 2013 Oct;47(10):1280-91. doi: 10.1177/1060028013503624..
Keywords: Diabetes, Medication, Comparative Effectiveness